Theravance Biopharma TBPH Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $105.9M+288% | -$56.42M-2.2% | -$55.19M-106% | $872.13M+537% | ||
| $1.63M-4.9% | $1.71M-14.5% | $2M-46.2% | $3.72M-22.6% | ||
| $18.48M-13.6% | $21.39M-15.7% | $25.37M-36.1% | $39.73M-36.0% | ||
| —— | -$7.66M-339% | $3.21M— | —— | ||
| $326K-56.6% | $752K— | —— | —— | ||
| —— | —— | -$7.1M— | —— | ||
| —— | —— | $1.23M-67.6% | $3.8M+278% | ||
| —— | -$532K-107% | $7.55M+1,538% | -$525K— | ||
| $95K— | —— | —— | —— | ||
| $4.02M-9.0% | $4.41M+6.3% | $4.15M+4.1% | $3.99M— | ||
| -$7.12M-1,177% | $661K— | —— | -$1.11M+68.0% | ||
| —— | -$11.54M+57.3% | -$27M+85.6% | -$186.99M+10.0% | ||
| $248.22M+76.4% | $140.74M— | —— | $103.15M-34.8% | ||
| $142.98M+2.3% | $139.81M— | —— | $158M-44.8% | ||
| -$105.87M— | —— | —— | $1.15B— | ||
| —— | —— | —— | —— | ||
| $4.03M+51.7% | $2.66M+6.4% | $2.5M-27.5% | $3.45M-61.9% | ||
| -$3.25M-30.1% | -$2.5M+98.7% | -$198.93M+73.8% | -$758.95M-906% | ||
| —— | —— | -$258.63M— | —— | ||
| $27.88M+25,482% | $109K+354% | $24K— | —— | ||
| $2.83M+12.8% | $2.51M+32.3% | $1.9M+179% | $681K— | ||
| -$7.12M-1,177% | $661K— | —— | -$1.11M+68.0% | ||
| —— | -$532K-107% | $7.55M+1,538% | -$525K— | ||
| —— | —— | $1.23M-67.6% | $3.8M+278% | ||
| —— | -$1.97M-474% | $526K+106% | -$9.07M+10.5% | ||
| $3.36M— | —— | $3.92M— | —— | ||
| —— | —— | —— | —— | ||
| $27.1M+2,705% | $966K+40.2% | $689K-74.7% | $2.72M— | ||
| —— | $707K+325% | -$314K— | —— | ||
| $2.46M-3.3% | $2.55M+8.3% | $2.35M— | —— | ||
| $4.02M-9.0% | $4.41M+6.3% | $4.15M+4.1% | $3.99M— | ||
| $1.63M-4.9% | $1.71M-14.5% | $2M-46.2% | $3.72M-22.6% | ||
| $95K— | —— | —— | —— | ||
| $10.48M+5.8% | $9.91M+799% | $1.1M-98.3% | $63.95M+33,937% | ||
| $142.98M+2.3% | $139.81M— | —— | $158M-44.8% | ||
| -$7.12M-1,177% | $661K— | —— | -$1.11M+68.0% | ||
| —— | $2.29M— | —— | —— | ||
| $27.88M+25,482% | $109K+354% | $24K— | —— | ||
| $238.5M+2,110% | -$11.87M+59.8% | -$29.49M+84.3% | -$187.56M+11.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Theravance Biopharma generate?
- Theravance Biopharma (TBPH) generated $323.5M in operating cash flow over the trailing twelve months.
- Where does Theravance Biopharma's cash flow data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
